Endocrine and Targeted Manipulation of Breast Cancer
Sixth Cambridge Conference
May 2007
Endocrine Manipulation of Breast Cancer: Summary Statement from the 6th Cambridge Conference
Steven E. Come, Aman U. Buzdar , James N. Ingle, Stephen RD Johnston, Angela M. Brodie, Charles Coombes, William R. Miller, Kathleen I. Pritchard, Eric P. Winer, Jo Anne Zujewski, Paul E. Goss
Preclinical Modeling of Endocrine Response and Resistance: Focus on Aromatase Inhibitors
Luciana F. Macedo, Gauri Sabnis, Angela Brodie
Predicting Response and Resistance to Endocrine Therapy: Profiling Patients on Aromatase Inhibitors
William R Miller, Alexey Larionov, Thomas J Anderson, John R Walker, Andreas Krause, Dean B Evans, and J Michael Dixon
Pharmacogenomics of tamoxifen and aromatase inhibitors
James N. Ingle
Summary of Aromatase Inhibitor Clinical Trials in Postmenopausal Women with Early Breast Cancer
Aman U. Buzdar, Charles Coombes, Paul E. Goss, Eric P. Winer
Enhancing Endocrine Response with Novel Targeted Therapies – Why Have the Clinical Trials to date Failed to Deliver on the Pre-clinical Promise?
Stephen RD Johnston
Combining Endocrine Agents with Chemotherapy: Which Patients and What Sequence?
Kathleen I. Pritchard
Current NCI-sponsored Cooperative Group Trials of Endocrine Therapies in Breast Cancer
Jennifer Eng-Wong, Jo Anne Zujewski
